NCT04049825View on ClinicalTrials.gov

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Relapsed or Refractory Diffuse Large B-cell Lymphoma
Interventions
DRUG

OPB-111077

OPB-111077+bendamustine

DRUG

OPB-111077

OPB-111077+rituximab+bendamustine

Trial Locations (1)

Unknown

Yamagata University Hospital, Yamagata

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY